For the sub-groups of patients responding or non-responding to the ACTH test, no significant differences in norepinephrine weaning were noted (HR 1.84, 95% CI 0.67, 5.05, P = 0.23 and HR 6.74, 95% CI 0.82, 55.19, P = 0.07, respectively).> -wrap-foot> Varying dose in unweaned patients = (norepinephrin end dosing – norepinephrin initial dosing)/norepinephrin initial dosing.
Eletriptan 80 mg, a higher-end dose of this triptan, was associated with the highest incidence of AEs, and almotriptan 12.5 mg the lowest incidence (Fig. 2).
Methods: To begin to answer this question, several case studies were examined where apical end point dose response curves were compared to dose response data on epigenetic end points for 1,3-butadiene, arsenic, and diethylstilbesterol.
Point estimates again suggest a consistent pattern favoring desloratadine patient satisfaction, with statistically significant results reported for sum of adverse events, end of dose failure – nighttime awakenings, end of dose failure – morning symptoms, and overall satisfaction with current Rx (p < 0.05).
This work evaluates the effect of auditory rhythmic stimulation on PD+FOG at the end of dose. 10 PD+FOG and 9 PD-FOG patients both at the end of dose periods, and 10 healthy controls were asked to perform several walking tasks.
In this paradigm we used a frequency of stimulation determined during the ON period, to be used at the end of dose time epoch.
We conclude that auditory stimulation may be used in order to minimize FOG at the end of dose in affected Parkinsonian patients.
End of dose was defined as "deterioration and recurrence of parkinsonian symptoms as a result of shorter (sometimes only 1 to 2 hours) duration of benefit after a given dose of L-dopa".
It is known that auditory rhythmic stimulation improves gait in patients without FOG (PD-FOG), but its putative effect on patients with FOG (PD+FOG) at the end of dose has not been evaluated yet.
Results from our study support the use of a frequency slightly above the preferred walking frequency (as measured during ON-periods in absence of FOG), which can then be used at the end of dose phase.
